Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact
Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: SPHK1

Gene summary for SPHK1

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

SPHK1

Gene ID

8877

Gene namesphingosine kinase 1
Gene AliasSPHK
Cytomap17q25.1
Gene Typeprotein-coding
GO ID

GO:0000165

UniProtAcc

Q53ZR5


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
8877SPHK1GSM5276934HumanEndometriumEEC2.12e-246.27e-01-0.0913
8877SPHK1GSM5276937HumanEndometriumEEC7.70e-377.68e-01-0.0897
8877SPHK1LZE22THumanEsophagusESCC1.81e-055.40e-010.068
8877SPHK1LZE24THumanEsophagusESCC2.38e-062.21e-010.0596
8877SPHK1LZE21THumanEsophagusESCC2.91e-036.30e-010.0655
8877SPHK1P1T-EHumanEsophagusESCC1.65e-065.83e-010.0875
8877SPHK1P2T-EHumanEsophagusESCC2.35e-388.02e-010.1177
8877SPHK1P4T-EHumanEsophagusESCC1.80e-237.28e-010.1323
8877SPHK1P5T-EHumanEsophagusESCC1.42e-114.61e-010.1327
8877SPHK1P8T-EHumanEsophagusESCC2.32e-021.54e-010.0889
8877SPHK1P9T-EHumanEsophagusESCC1.30e-266.80e-010.1131
8877SPHK1P10T-EHumanEsophagusESCC4.24e-461.16e+000.116
8877SPHK1P11T-EHumanEsophagusESCC3.16e-321.32e+000.1426
8877SPHK1P12T-EHumanEsophagusESCC1.60e-348.20e-010.1122
8877SPHK1P15T-EHumanEsophagusESCC1.23e-271.11e+000.1149
8877SPHK1P16T-EHumanEsophagusESCC1.61e-631.40e+000.1153
8877SPHK1P17T-EHumanEsophagusESCC2.20e-106.24e-010.1278
8877SPHK1P19T-EHumanEsophagusESCC1.03e-171.63e+000.1662
8877SPHK1P20T-EHumanEsophagusESCC2.81e-531.26e+000.1124
8877SPHK1P21T-EHumanEsophagusESCC1.31e-379.85e-010.1617
Page: 1 2 3 4 5 6 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
EndometriumThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AEH: Atypical endometrial hyperplasia
EEC: Endometrioid Cancer
EsophagusThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ESCC: Esophageal squamous cell carcinoma
HGIN: High-grade intraepithelial neoplasias
LGIN: Low-grade intraepithelial neoplasias
LiverThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.HCC: Hepatocellular carcinoma
NAFLD: Non-alcoholic fatty liver disease
Oral CavityThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.EOLP: Erosive Oral lichen planus
LP: leukoplakia
NEOLP: Non-erosive oral lichen planus
OSCC: Oral squamous cell carcinoma
ProstateThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.BPH: Benign Prostatic Hyperplasia
SkinThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AK: Actinic keratosis
cSCC: Cutaneous squamous cell carcinoma
SCCIS:squamous cell carcinoma in situ
ThyroidThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ATC: Anaplastic thyroid cancer
HT: Hashimoto's thyroiditis
PTC: Papillary thyroid cancer
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
GO:00002802EsophagusESCCnuclear division270/8552439/187231.17e-114.24e-10270
GO:0000302111EsophagusESCCresponse to reactive oxygen species150/8552222/187233.06e-111.02e-09150
GO:0016049110EsophagusESCCcell growth289/8552482/187231.29e-103.77e-09289
GO:190332216EsophagusESCCpositive regulation of protein modification by small protein conjugation or removal99/8552138/187234.39e-101.16e-0899
GO:004578710EsophagusESCCpositive regulation of cell cycle196/8552313/187239.27e-102.24e-08196
GO:0042542111EsophagusESCCresponse to hydrogen peroxide102/8552146/187232.64e-095.81e-08102
GO:000155819EsophagusESCCregulation of cell growth248/8552414/187232.97e-096.45e-08248
GO:003010018EsophagusESCCregulation of endocytosis135/8552211/187235.75e-081.02e-06135
GO:00070883EsophagusESCCregulation of mitotic nuclear division78/8552110/187236.96e-081.21e-0678
GO:003109818EsophagusESCCstress-activated protein kinase signaling cascade154/8552247/187238.53e-081.44e-06154
GO:00066433EsophagusESCCmembrane lipid metabolic process130/8552203/187239.29e-081.54e-06130
GO:003461420EsophagusESCCcellular response to reactive oxygen species103/8552155/187231.34e-072.17e-06103
GO:003139816EsophagusESCCpositive regulation of protein ubiquitination82/8552119/187232.41e-073.64e-0682
GO:004593116EsophagusESCCpositive regulation of mitotic cell cycle83/8552121/187232.78e-074.08e-0683
GO:00482844EsophagusESCCorganelle fusion94/8552141/187233.72e-075.16e-0694
GO:00510908EsophagusESCCregulation of DNA-binding transcription factor activity252/8552440/187235.22e-076.97e-06252
GO:005140318EsophagusESCCstress-activated MAPK cascade147/8552239/187235.43e-077.18e-06147
GO:00703018EsophagusESCCcellular response to hydrogen peroxide68/855298/187231.70e-062.03e-0568
GO:00607595EsophagusESCCregulation of response to cytokine stimulus103/8552162/187233.14e-063.53e-05103
GO:00510918EsophagusESCCpositive regulation of DNA-binding transcription factor activity155/8552260/187233.83e-064.14e-05155
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
hsa0407116EsophagusESCCSphingolipid signaling pathway85/4205121/84653.04e-061.73e-058.84e-0685
hsa051527EsophagusESCCTuberculosis111/4205180/84657.14e-042.32e-031.19e-03111
hsa0466620EsophagusESCCFc gamma R-mediated phagocytosis63/420597/84651.63e-034.89e-032.50e-0363
hsa006003EsophagusESCCSphingolipid metabolism36/420553/84655.41e-031.36e-026.99e-0336
hsa0407117EsophagusESCCSphingolipid signaling pathway85/4205121/84653.04e-061.73e-058.84e-0685
hsa0515212EsophagusESCCTuberculosis111/4205180/84657.14e-042.32e-031.19e-03111
hsa04666110EsophagusESCCFc gamma R-mediated phagocytosis63/420597/84651.63e-034.89e-032.50e-0363
hsa0060012EsophagusESCCSphingolipid metabolism36/420553/84655.41e-031.36e-026.99e-0336
hsa040718LiverHCCSphingolipid signaling pathway72/4020121/84655.01e-031.47e-028.18e-0372
hsa0466610LiverHCCFc gamma R-mediated phagocytosis58/402097/84659.65e-032.52e-021.40e-0258
hsa00600LiverHCCSphingolipid metabolism34/402053/84651.06e-022.71e-021.51e-0234
hsa0407111LiverHCCSphingolipid signaling pathway72/4020121/84655.01e-031.47e-028.18e-0372
hsa0466611LiverHCCFc gamma R-mediated phagocytosis58/402097/84659.65e-032.52e-021.40e-0258
hsa006001LiverHCCSphingolipid metabolism34/402053/84651.06e-022.71e-021.51e-0234
hsa0407114Oral cavityOSCCSphingolipid signaling pathway82/3704121/84656.97e-085.08e-072.58e-0782
hsa051526Oral cavityOSCCTuberculosis105/3704180/84655.00e-052.04e-041.04e-04105
hsa0466618Oral cavityOSCCFc gamma R-mediated phagocytosis60/370497/84652.35e-047.72e-043.93e-0460
hsa04370Oral cavityOSCCVEGF signaling pathway37/370459/84652.53e-036.62e-033.37e-0337
hsa006002Oral cavityOSCCSphingolipid metabolism33/370453/84655.00e-031.20e-026.13e-0333
hsa0407115Oral cavityOSCCSphingolipid signaling pathway82/3704121/84656.97e-085.08e-072.58e-0782
Page: 1 2 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
SPHK1SNVMissense_Mutationrs149492135c.1055N>Tp.Ser352Leup.S352LQ9NYA1protein_codingdeleterious(0)possibly_damaging(0.755)TCGA-A7-A26E-01Breastbreast invasive carcinomaFemale>=65III/IVChemotherapycytoxanSD
SPHK1deletionFrame_Shift_Delc.290_303delTCCCGCGGCCCTGCp.Leu97ProfsTer29p.L97Pfs*29Q9NYA1protein_codingTCGA-D8-A1JG-01Breastbreast invasive carcinomaFemale<65I/IIChemotherapydoxorubicinSD
SPHK1SNVMissense_Mutationrs866618568c.812N>Ap.Arg271Glnp.R271QQ9NYA1protein_codingdeleterious(0)probably_damaging(0.985)TCGA-2W-A8YY-01Cervixcervical & endocervical cancerFemale<65I/IIChemotherapycisplatinCR
SPHK1SNVMissense_Mutationc.961G>Cp.Asp321Hisp.D321HQ9NYA1protein_codingdeleterious(0.03)possibly_damaging(0.847)TCGA-DS-A0VN-01Cervixcervical & endocervical cancerFemale<65I/IIChemotherapycisplatinSD
SPHK1SNVMissense_Mutationnovelc.510G>Ap.Met170Ilep.M170IQ9NYA1protein_codingtolerated(0.24)benign(0.003)TCGA-CK-4951-01Colorectumcolon adenocarcinomaFemale>=65I/IIUnknownUnknownPD
SPHK1deletionFrame_Shift_Delc.1160delGp.Arg387ProfsTer44p.R387Pfs*44Q9NYA1protein_codingTCGA-AA-3663-01Colorectumcolon adenocarcinomaMale<65I/IIUnknownUnknownSD
SPHK1SNVMissense_Mutationrs773839692c.1133N>Tp.Ala378Valp.A378VQ9NYA1protein_codingdeleterious(0)benign(0.325)TCGA-A5-A0VP-01Endometriumuterine corpus endometrioid carcinomaFemale>=65I/IIUnknownUnknownSD
SPHK1SNVMissense_Mutationrs775563147c.255N>Tp.Glu85Aspp.E85DQ9NYA1protein_codingtolerated(0.08)benign(0.06)TCGA-AJ-A3EL-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIUnknownUnknownSD
SPHK1SNVMissense_Mutationnovelc.713N>Cp.Leu238Prop.L238PQ9NYA1protein_codingdeleterious(0)possibly_damaging(0.637)TCGA-AP-A1DK-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIUnknownUnknownSD
SPHK1SNVMissense_Mutationnovelc.1220N>Gp.Tyr407Cysp.Y407CQ9NYA1protein_codingtolerated(0.1)benign(0.047)TCGA-AX-A1CE-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIUnspecificPaclitaxelSD
Page: 1 2 3 4 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
8877SPHK1ENZYME, KINASE, LIPID KINASE, DRUGGABLE GENOMEPMID27539678-Compound-11
8877SPHK1ENZYME, KINASE, LIPID KINASE, DRUGGABLE GENOMEABC294640
8877SPHK1ENZYME, KINASE, LIPID KINASE, DRUGGABLE GENOMEinhibitor404859088
8877SPHK1ENZYME, KINASE, LIPID KINASE, DRUGGABLE GENOMEPMID27539678-Compound-13
8877SPHK1ENZYME, KINASE, LIPID KINASE, DRUGGABLE GENOMEGSK618334
8877SPHK1ENZYME, KINASE, LIPID KINASE, DRUGGABLE GENOMEinhibitor178103235
8877SPHK1ENZYME, KINASE, LIPID KINASE, DRUGGABLE GENOMEPMID27539678-Compound-16
8877SPHK1ENZYME, KINASE, LIPID KINASE, DRUGGABLE GENOMEPMID27539678-Compound-7
8877SPHK1ENZYME, KINASE, LIPID KINASE, DRUGGABLE GENOMEinhibitor381744899
8877SPHK1ENZYME, KINASE, LIPID KINASE, DRUGGABLE GENOMEMethylbenzenesulfonamide derivative 1
Page: 1 2 3